AUA Chicago April 28 – May 1, 2023- Here We Come
Our very own Neal D. Shore, MD, FACS, CURC Director, CPI (Certified Principal Investigator by the Association of Clinical Research Professionals) and Jennifer Sutton, RN, Certified Clinical Research Coordinator, Director of Nursing and Administration, will be attending AUA (American Urological Association) in Chicago at the end of April. https://www.auanet.org/aua2023
Dr. Shore will also be co-moderating an Independent Practice Symposium being Saturday, April 29, 2023, from 7:30 – 11:30 am CT at the AUA Annual Meeting in Chicago. #amerurological
Perioperative Pembrolizumab Therapy In Muscle-Invasive Bladder Cancer: Phase III KEYNOTE-866 And KEYNOTE-905/EV-303
Matthew D Galsky, Christopher J Hoimes, Andrea Necchi, Neal Shore, J Alfred Witjes, Gary Steinberg, Jens Bedke, Hiroyuki Nishiyama, Xiao Fang, Ritesh Kataria, Eric Sbar, Xieyang Jia & Arlene Siefker-Radtke
Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia
Bilal Chughtai, Sirikan Rojanasarot, Kurt Neeser, Dmitry Gultyaev, Stacey L. Amorosi, Neal D. Shore
Efficacy of Enzalutamide Plus Androgen Deprivation Therapy In Metastatic Hormone-Sensitive Prostate Cancer By Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
Andrew J. Armstrong, Neal D. Shore, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Francisco Gomez-Veiga, Brad Rosbrook, Ho-Jin Lee, Gabriel P. Haas, and Arnulf Stenzl
Comparison of Germline Mutations In African American And Caucasian Men With Metastatic Prostate Cancer
Elisa M. Ledet PhD, Earle F. Burgess MD, Alexandra O. Sokolova MD, Ellen B. Jaeger BS, Whitley Hatton MS, Marcus Moses MS, Patrick Miller MPH, Patrick Cotogno MS, Jodi Layton MD, Pedro Barata MD, Brian E. Lewis MD, Mari Nakazawa MD, Jason Zhu MD, Beth Dellinger MS, Sara Elrefai MD, Nellie N. Nafissi MD, Jan B. Egan PhD, Neal Shore MD, Rana R. McKay MD, Alan H. Bryce MD, Heather H. Cheng MD, PhD, Emmanuel S. Antonarakis MD, Oliver Sartor MD
Click here to register for free to gain access to the article.
Niraparib With Androgen Receptor-Axis-Targeted Therapy In Patients With Metastatic Castration-Resistant Prostate Cancer: Safety And Pharmacokinetic Results From A Phase 1b Study (BEDIVERE)
Fred Saad, Kim N. Chi, Neal D. Shore, Julie N. Graff, Edwin M. Posadas, Jean-Baptiste Lattouf, Byron M. Espina, Eugene Zhu, Alex Yu, Anasuya Hazra, Marc De Meulder, Rao N. V. S. Mamidi, Branislav Bradic, Peter Francis, Vinny Hayreh & Arash Rezazadeh Kalebasty
Combined Advanced Prostate Cancer Treatments- Are They Additive?
Abhishek Srivastava & Neal D. Shore
Treatment of Nonmetastatic Castration- Resistant Prostate Cancer: Focus On Second-Generation Androgen Receptor Inhibitors
Fred Saad, Martin Bögemann, Kazuhiro Suzuki & Neal Shore
Treating The Patient And Not Just The Cancer: Therapeutic Burden In Prostate Cancer
Daniel E. Spratt, Neal Shore, Oliver Sartor, Dana Rathkopf & Kara Olivier
Our Affiliates
